Historique
Article de Périodique
Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus (2017)
Auteur(s) :
DEMATTEIS, M. ;
AURIACOMBE, M. ;
D'AGNONE, O. ;
SOMAINI, L. ;
SZERMAN, N. ;
LITTLEWOOD, R. ;
ALAM, F. ;
ALHO, H. ;
BENYAMINA, A. ;
BOBES, J. ;
DAULOUEDE, J. P. ;
LEONARDI, C. ;
MAREMMANI, I. ;
TORRENS, M. ;
WALCHER, S. ;
SOYKA, M.
Année
2017
Page(s) :
1987-1999
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Refs biblio. :
114
Domaine :
Autres substances / Other substances ; Drogues illicites / Illicit drugs
Thésaurus géographique
EUROPE
Thésaurus mots-clés
RECOMMANDATION
;
OPIOIDES
;
TRAITEMENT DE MAINTENANCE
;
BUPRENORPHINE
;
METHADONE
;
PHARMACOTHERAPIE
;
SURDOSE
;
REDUCTION DES RISQUES ET DES DOMMAGES
Résumé :
Introduction: Management of patients with opioid use disorder (OUD) commonly includes opioid agonist therapy (OAT) as a part of an integrated treatment plan. These interventions are associated with proven benefits to the individual and society.
Areas covered: The use of methadone and buprenorphine within an integrated treatment plan in the management of patients with OUD: this work provides consensus recommendation on pharmacotherapy in OUD to assist clinicians with practical decision making in this field.
Expert opinion: Pharmacotherapy is recommended as part of an integrated OUD treatment approach with psychosocial interventions, with the goal of reducing risks of illicit opioid use, overdose mortality, infection with HIV or HCV, improving health, psychological and social outcomes. Access to OAT should be prioritised in the treatment of OUD. Treatment choices in OUD pharmacotherapy should be based on the needs of the individual and characteristics of medications. Recommendations for choices of OAT are based on clinical efficacy, safety, patient preference, side effects, pharmacological interactions, quality of life, dose titration potential and outcomes (control craving, ongoing opioids consumption or other drugs, and potentially psychiatric comorbidities). Special groups, pregnant women, prisoners, patients with mental health problems have specific needs which must be addressed with expert input.
Areas covered: The use of methadone and buprenorphine within an integrated treatment plan in the management of patients with OUD: this work provides consensus recommendation on pharmacotherapy in OUD to assist clinicians with practical decision making in this field.
Expert opinion: Pharmacotherapy is recommended as part of an integrated OUD treatment approach with psychosocial interventions, with the goal of reducing risks of illicit opioid use, overdose mortality, infection with HIV or HCV, improving health, psychological and social outcomes. Access to OAT should be prioritised in the treatment of OUD. Treatment choices in OUD pharmacotherapy should be based on the needs of the individual and characteristics of medications. Recommendations for choices of OAT are based on clinical efficacy, safety, patient preference, side effects, pharmacological interactions, quality of life, dose titration potential and outcomes (control craving, ongoing opioids consumption or other drugs, and potentially psychiatric comorbidities). Special groups, pregnant women, prisoners, patients with mental health problems have specific needs which must be addressed with expert input.
Affiliation :
Department of Addiction Medicine, Grenoble Alpes University Hospital, Grenoble, France
- voir aussi :
- Courrier des Addictions (Le), Approches thérapeutiques du trouble de l'usage des opiacés et opioïdes / M. DEMATTEIS ; G. BROUSSE (2019)
- Alcoologie et Addictologie, Recommandations pour le traitement du trouble de l'usage des opioïdes par la buprénorphine et la méthadone. Consensus européen / M. DEMATTEIS ; M. AURIACOMBE ; O. D'AGNONE ; L. SOMAINI ; N. SZERMAN ; R. LITTLEWOOD ; F. ALAM ; H. ALHO ; A. BENYAMINA ; J. BOBES ; J. P. DAULOUEDE ; C. LEONARDI ; I. MAREMMANI ; M. TORRENS ; S. WALCHER ; M. SOYKA (2019)